Baidu
map

Lancet:非洲新冠肺炎防控能力评估

2020-03-14 MedSci原创 MedSci原创

2019年新型冠状病毒肺炎(COVID-19)疫情已蔓延至25个国家。在病例输入后,已有12个国家出现了本地传播。在非洲,目前埃及已确认一例病例。COVID-19输入管理和控制很大程度上依赖于一个国家

2019年新型冠状病毒肺炎(COVID-19)疫情已蔓延至25个国家。在病例输入后,已有12个国家出现了本地传播。在非洲,目前埃及已确认一例病例。COVID-19输入管理和控制很大程度上依赖于一个国家的卫生能力。近日研究人员就非洲国家应对COVID-19疫情的能力进行了评估。

研究人员通过统计中国疫区与非洲之间的直飞航班量数据来估计每个国家的输入风险。采用两个指标评估一个国家发现和应对病例的能力:警戒性,依据WHO国际卫生条例监测和评价框架;脆弱性,依据传染病脆弱性指数。根据中国地区对风险的贡献最大,将国家分组。

疫情输入风险最高的国家,如埃及、阿尔及利亚和南非,有中等到较高的疫情应对能力。处于中等风险国家,如尼日利亚、埃塞俄比亚、苏丹、安哥拉、坦桑尼亚、加纳和肯尼亚,疫情应对能力不一,脆弱性很高。。研究人员确定了三类国家,它们分别承受来自广东、福建和北京等地区的相同风险

研究认为,非洲针对新冠肺炎疫情资源和强化监控应优先在中等风险国家中考虑,这些国家可能不足以应对病毒的输入和限制其继续传播。

原始出处:

Marius Gilbert et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet. February 20, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830515, encodeId=90f718305153d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 19:20:35 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813737, encodeId=0022813e3743, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:05:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816275, encodeId=250e18162e542, content=<a href='/topic/show?id=f0c49e403b9' target=_blank style='color:#2F92EE;'>#防控能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97403, encryptionId=f0c49e403b9, topicName=防控能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Sep 04 06:20:35 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027439, encodeId=40f9102e43956, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 13:20:35 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-12-03 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830515, encodeId=90f718305153d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 19:20:35 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813737, encodeId=0022813e3743, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:05:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816275, encodeId=250e18162e542, content=<a href='/topic/show?id=f0c49e403b9' target=_blank style='color:#2F92EE;'>#防控能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97403, encryptionId=f0c49e403b9, topicName=防控能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Sep 04 06:20:35 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027439, encodeId=40f9102e43956, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 13:20:35 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1830515, encodeId=90f718305153d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 19:20:35 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813737, encodeId=0022813e3743, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:05:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816275, encodeId=250e18162e542, content=<a href='/topic/show?id=f0c49e403b9' target=_blank style='color:#2F92EE;'>#防控能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97403, encryptionId=f0c49e403b9, topicName=防控能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Sep 04 06:20:35 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027439, encodeId=40f9102e43956, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 13:20:35 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830515, encodeId=90f718305153d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 19:20:35 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813737, encodeId=0022813e3743, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:05:32 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816275, encodeId=250e18162e542, content=<a href='/topic/show?id=f0c49e403b9' target=_blank style='color:#2F92EE;'>#防控能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97403, encryptionId=f0c49e403b9, topicName=防控能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Sep 04 06:20:35 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027439, encodeId=40f9102e43956, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Mar 14 13:20:35 CST 2020, time=2020-03-14, status=1, ipAttribution=)]
    2020-03-14 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

恐怖地带:埃博拉为何肆虐非洲

短短一周内,因埃博拉病毒致死的人数,已从729人上涨到826人——疾病蔓延的速度大大高于控制它的速度,世界卫生组织为此大呼“失控”。已在西非肆虐、没有任何疫苗和针对性治疗方式的埃博拉病毒,也已导致60余位一线医护工作者死亡。 自 20 世纪 70 年代中期首次发现该疾病以来,此次爆发的疫情为最严重的一次。埃博拉病毒的致死率高达90%,是sars病毒致死率的6倍。它,在西非之外已有病例

默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准

默克公司的埃博拉疫苗Ervebo已在四个非洲国家(包括受该病影响最严重的国家--刚果民主共和国)获得批准。去年,默克公司成为第一个获得美国食品药品监督管理局和欧洲药品管理局批准的埃博拉疫苗的药物开发商。

Lancet Infect Dis:多模式干预能否改善非洲国家手术部位感染情况?

2018年5月,发表在《Lancet Infect Dis》的一项由瑞士、英国、肯尼亚、乌干达等国家进行的前-后队列研究,考察了多模式感染控制和患者安全性干预能否改善非洲国家手术部位感染的情况。

Baidu
map
Baidu
map
Baidu
map